Factors Related to the Progression of Chronic Kidney Disease
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01317173|
Recruitment Status : Unknown
Verified January 2011 by Ankara Education and Research Hospital.
Recruitment status was: Active, not recruiting
First Posted : March 17, 2011
Last Update Posted : March 17, 2011
|Condition or disease|
|Chronic Kidney Disease|
|Study Type :||Observational|
|Estimated Enrollment :||90 participants|
|Official Title:||The Impact of FGF23 and Klotho on Progression of Chronic Kidney Disease|
|Study Start Date :||March 2008|
|Estimated Primary Completion Date :||May 2011|
|Estimated Study Completion Date :||June 2011|
Serum creatinin level rise more than 2 times
Serum creatinin level rise less than 2 times
- Progression of kidney disease [ Time Frame: continuous measurement of kidney functions 3 monthly for two years or until the outcome reached ]Doubling of creatinin, requirement of renal replacement therapy
- Evaluation of Ca P metabolism [ Time Frame: 3 monthly for two years or until the outcome reached ]Determination of Ca-P metabolism disorders.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01317173
|Ankara Education and Research Hospital|